Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jul 11 2025

Full Issue

Common Pain Drug Gabapentin Linked To Dementia Diagnoses In Adults

Research shows that patients with six or more prescriptions for gabapentin, commonly used to treat lower back pain, were 29% more likely to be diagnosed with dementia and 85% more likely to be diagnosed with mild cognitive impairment within 10 years of their initial pain diagnosis.

Newsweek: Dementia Diagnoses Rise In Adults Prescribed With Common Pain Drug

A commonly prescribed pain medication — gabapentin — often considered a safer alternative to opioids for those who suffer from low back pain is now under scrutiny after being linked to increased risks of dementia and mild cognitive impairment (MCI). According to a large-scale observational study published in the journal Regional Anesthesia & Pain Medicine, patients who received frequent gabapentin prescriptions were significantly more likely to develop dementia and/or MCI. (Azzurra Volpe, 7/10)

CIDRAP: Screening All Patients For Hepatitis C Testing In ED May Find More Cases Than Targeted Approach

A new randomized clinical trial conducted at three US emergency departments (EDs) concludes that screening all adults for hepatitis C virus (HCV) testing identifies significantly more cases than screening based on individual patient risk, although low proportions sought treatment. (Van Beusekom, 7/10)

MedPage Today: Combo Therapy Boosts Survival In Resectable Biliary Tract Cancer

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic cholangiocarcinoma [EHC] and gallbladder cancer [GBC]) in a randomized phase II Chinese study. (Bassett, 7/10)

CIDRAP: In 2 Trials, Less Toxic TB Antibiotics Show Promise

The newly published results of two small clinical trials suggest that two novel antibiotics could provide safer alternatives to a highly toxic antibiotic currently used in drug-resistant tuberculosis (DR-TB) treatment regimens. (Dall, 7/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF